Emicerfont
Alternative Names: 876008; GW 876008; GW876008XLatest Information Update: 02 Jul 2023
At a glance
- Originator GlaxoSmithKline; Neurocrine Biosciences
- Developer GlaxoSmithKline
- Class Antidepressants; Anxiolytics; Irritable bowel syndrome therapies; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Irritable bowel syndrome; Major depressive disorder
Most Recent Events
- 25 Nov 2009 Pharmacodynamics data from a phase II trial in Irritable bowel syndrome presented at GASTRO 2009 Joint Meeting (GASTRO-2009)
- 30 Sep 2009 Clinical development is ongoing in USA
- 05 Feb 2008 GlaxoSmithKline completes a Phase-II trial in Anxiety disorders in the US, Canada, the EU and South Africa